Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Frankel

Burien, WA Medical Doctor

NPI 1487694154 CMS profile 249250

16259 Sylvester Rd Sw Ste 303, 303, Burien, WA 98166

Open in the dashboard

General payments

$393,410

480 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$121,207 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Jeffrey Frankel of Burien, WA is reported in the CMS Open Payments database as having received $393,410 across 480 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $121,207 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $51,063 33
2024 General $50,645 51
2023 General $119,360 99
2022 General $78,742 70
2021 General $34,233 68
2020 General $32,875 62
2019 General $26,492 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Frankel
  • Washington median
  • Middle half of Washington
  • National median

In program year 2025, general payments to Jeffrey Frankel were reported at $51,063. Among 15,799 Washington profiles paid that year, the median was $133 and the middle half received between $42 and $442.

Show as a table
Year Jeffrey Frankel Washington median Middle half National median
2019 $26,492 $126 $38–$506 $163
2020 $32,875 $90 $30–$291 $114
2021 $34,233 $107 $29–$344 $132
2022 $78,742 $124 $38–$398 $149
2023 $119,360 $129 $40–$423 $160
2024 $50,645 $133 $44–$454 $164
2025 $51,063 $133 $42–$442 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sumitomo Pharma America, Inc. $209,833 160 payments
  2. Myovant Sciences Inc. $65,357 46 payments
  3. Astellas Pharma US Inc $55,745 76 payments
  4. Pfizer Inc. $25,207 37 payments
  5. TOLMAR Pharmaceuticals, Inc. $17,407 10 payments
  6. Urovant Sciences Inc $9,575 15 payments
  7. AstraZeneca Pharmaceuticals LP $3,443 6 payments
  8. Myovant Sciences GmbH $1,531 8 payments
  9. Janssen Scientific Affairs, LLC $834 5 payments
  10. Dendreon Pharmaceuticals LLC $477 14 payments
  11. Other $4,001 103 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $267,832 100 payments
  2. Consulting Fee $73,038 25 payments
  3. Travel and Lodging $40,252 112 payments
  4. Food and Beverage $11,620 230 payments
  5. Education $635 12 payments
  6. Entertainment $34 1 payment
Products named General payments · program years 2019–2025
  1. ORGOVYX Hormone Therapy $146,501 111 payments
  2. GEMTESA Urology $96,063 87 payments
  3. XTANDI $40,483 71 payments
  4. MYRBETRIQ $24,086 31 payments
  5. ORGOVYX Prostate Cancer $22,770 17 payments
  6. ELIGARD $17,407 10 payments
  7. GEMTESA Urology $10,485 10 payments
  8. ORGOVYX Oncology $5,885 13 payments
  9. LYNPARZA $3,443 6 payments
  10. TALZENNA $2,160 6 payments
  11. Other $5,242 130 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

480 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record